Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Relay Therapeutics, Inc.
Advanced NRAS-Mutant Melanoma
Advanced NRAS-Mutant Solid Tumors
NRAS Mutation
NRAS G12D
NRAS G13R
This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the
safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor
activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced
NRAS-mutant melanoma and other solid tumo1 expand
This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors. Type: Interventional Start Date: Mar 2026 |
|
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
Colorectal Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Esophageal Cancer
Stomach Cancer
This study will test the safety and effectiveness of a drug called IM-1617 in
participants with solid tumors. Participants will have solid tumor cancer that has spread
through the body (metastatic) or cannot be removed with surgery (unresectable).
This study will have two parts. Part A will test i1 expand
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers. Type: Interventional Start Date: May 2026 |
|
Time Restricted Eating (TRE) in Bipolar Disorder
Massachusetts General Hospital
Bipolar Disorder (BD)
Bipolar Disorder Depression
Overweight (BMI > 30)
This is a randomized controlled trial investigating the effects of an 8-TRE intervention
compared to a wait list (control) on metabolic health and body composition in people
diagnosed with BD and who are currently obese and at least mildly depressed. Following a
1-week baseline assessment, particip1 expand
This is a randomized controlled trial investigating the effects of an 8-TRE intervention compared to a wait list (control) on metabolic health and body composition in people diagnosed with BD and who are currently obese and at least mildly depressed. Following a 1-week baseline assessment, participants will be randomized to either a TRE or the wait list (1-to-1 ratio) for 8 weeks. At baseline, Week 8 (post treatment), and Week 20 (follow-up), investigators will assess daily eating patterns for one week, followed by collection of fasting lipids, body weight and vital signs. At Week 4 (i.e., mid-treatment), the investigators will assess self-reported outcomes only. Participants assigned to the wait list condition will have the option of receiving the TRE intervention after 20 weeks. Type: Interventional Start Date: Jun 2026 |
|
BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention
Massachusetts General Hospital
Colorectal Cancer Prevention
Colorectal Adenoma
This research study is a prospective, single-arm clinical trial to assess the effect of a
dietary intervention for more plant-based and less animal-based food intake on secondary
bile acid production, gut microbiota, circulating biomarkers and gene expression
associated with colonic bile acid recep1 expand
This research study is a prospective, single-arm clinical trial to assess the effect of a dietary intervention for more plant-based and less animal-based food intake on secondary bile acid production, gut microbiota, circulating biomarkers and gene expression associated with colonic bile acid receptor activation and colorectal cancer. Type: Interventional Start Date: Jun 2026 |
|
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Chil1
State University of New York at Buffalo
Cystic Fibrosis (CF)
This is a longitudinal, observational epidemiological study designed to estimate the
prevalence of depression, anxiety, and behavior problems in children ages 18 months
through 11 years with cystic fibrosis (CF). expand
This is a longitudinal, observational epidemiological study designed to estimate the prevalence of depression, anxiety, and behavior problems in children ages 18 months through 11 years with cystic fibrosis (CF). Type: Observational Start Date: Jun 2025 |
|
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advan1
Abbott Medical Devices
Heart Failure
Heart Diseases
Cardiovascular Diseases
Pulmonary Hypertension
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the
HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of
ambulatory advanced heart failure patients who are not dependent on intravenous inotrope. expand
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope. Type: Interventional Start Date: Dec 2024 |
|
Bionic Pancreas in CFRD
Jaeb Center for Health Research
Cystic Fibrosis-related Diabetes
This multi-center randomized controlled trial (RCT) will compare efficacy and safety
endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP)
versus a control group using their usual care insulin delivery method and continuous
glucose monitoring (CGM) during a 13-week1 expand
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system and the Usual Care group will initiate use of the BP system. Type: Interventional Start Date: Sep 2024 |
|
fMRI in CardiaC arrEst With Uncertain Prognosis
Brigham and Women's Hospital
Cardiac Arrest
The goal of this observational study is to determine whether specific advanced MRI
measures are associated with functional outcomes in patients who are comatose after
cardiac arrest. The main question[s] it aims to answer are:
Aim 1: Determine if stimulus-based functional MRI (fMRI)-measured activ1 expand
The goal of this observational study is to determine whether specific advanced MRI measures are associated with functional outcomes in patients who are comatose after cardiac arrest. The main question[s] it aims to answer are: Aim 1: Determine if stimulus-based functional MRI (fMRI)-measured activations are independently associated with favorable neurological outcomes after cardiac arrest Aim 2: Determine if resting state functional MRI (rs-fMRI)-measured functional network connectivity is independently associated with favorable neurological outcomes after cardiac arrest. Aim 3: Determine if diffusion tensor imaging (DTI)-measured white matter integrity is associated with favorable neurological outcomes after cardiac arrest. Participants will undergo advanced MRI sequences at time of clinical MRI, and will be followed for 6 months post-arrest. Type: Observational Start Date: May 2024 |
|
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
Non-Small Cell Lung Cancer, NSCLC
KRAS, NRAS, HRAS-mutated NSCLC
KRAS G12C-mutated Solid Tumors, Lung Cancer
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
RAS G12D-mutated NSCLC
The purpose of this platform study is to evaluate the safety, tolerability,
pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as
a monotherapy or combined with Standard(s) of Care (SOC) or with each other.
The first four subprotocols include the following:
Subp1 expand
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805 Type: Interventional Start Date: Jan 2024 |
|
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
Beth Israel Deaconess Medical Center
Acute Respiratory Distress Syndrome
Respiratory Failure
The goal of this interventional study is to compare standard mechanical ventilation to a
lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress
Syndrome (ARDS). Participants will be ventilated according to one of two different
strategies. The main question the study h1 expand
The goal of this interventional study is to compare standard mechanical ventilation to a lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Participants will be ventilated according to one of two different strategies. The main question the study hopes to answer is whether the personalized ventilation strategy helps improve survival. Type: Interventional Start Date: Jun 2024 |
|
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Advanced Solid Tumors
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in
combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors. expand
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors. Type: Interventional Start Date: Sep 2023 |
|
Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.
Aptis Medical
Arthritis
Unstable Radial Head
Proximal Radioulnar Joint Instability
Decreased Motion at the Proximal Radioulnar Joint and/or the Radio-humeral Joint
A Prospective, Multi-Center, Single-Arm Clinical Trial of the safety and effectiveness of
the Aptis PRUJ prosthesis for the treatment of patients with proximal radial ulna joint
disorders expand
A Prospective, Multi-Center, Single-Arm Clinical Trial of the safety and effectiveness of the Aptis PRUJ prosthesis for the treatment of patients with proximal radial ulna joint disorders Type: Interventional Start Date: Apr 2024 |
|
TSC Biosample Repository and Natural History Database
National Tuberous Sclerosis Association
Tuberous Sclerosis
Lymphangioleiomyomatosis
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that
scientists can request to use in their research. The samples we collect are all linked to
clinical data in the TSC Natural History Database. The TSC Natural History Database
captures clinical data to document t1 expand
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively. Type: Observational [Patient Registry] Start Date: Jan 2016 |
|
Effectiveness and Implementation of a Clinician Decision Support System to Prevent Suicidal Behavio1
Massachusetts General Hospital
Suicide
Suicide, Attempted
The primary aim of this project are to evaluate a comprehensive, practice-ready, and
deployment-focused strategy for improving the prediction and prevention of suicide
attempts among a sample of 4,000 patients presenting to an ED with a psychiatric concern.
The first aim is to evaluate the effects1 expand
The primary aim of this project are to evaluate a comprehensive, practice-ready, and deployment-focused strategy for improving the prediction and prevention of suicide attempts among a sample of 4,000 patients presenting to an ED with a psychiatric concern. The first aim is to evaluate the effects of providing information about risk of patient suicidal behavior to ED clinicians. The investigators hypothesize that patients randomly assigned to have their clinician receive their risk score will have a lower rate of suicide attempts during 6-month follow-up and that this effect will be mediated by changes in clinician decision-making. Type: Interventional Start Date: Feb 2025 |
|
Oxytocin for Weight Loss in Adolescents
Massachusetts General Hospital
Obesity, Adolescent
Oxytocin
This is a randomized, double blind, placebo-controlled study of the effects of intranasal
oxytocin in youths with obesity, ages 10-18 years old. Subjects will be randomized to
receive intranasal oxytocin or placebo (1 spray per nostril, 4 times per day) for 12
weeks. Study visits include screening1 expand
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 10-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (1 spray per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, 2-part main study visits at baseline, week 8, and week 12, and safety check-in visits at weeks 1, and 4; phone calls at weeks 2, 6, and 10, with a safety follow-up visit 6 weeks after the last dose of study drug. Study procedures include appetite, behavioral, metabolic, and endocrine assessments. Type: Interventional Start Date: Jul 2021 |
|
Pompe Disease Registry Protocol
Genzyme, a Sanofi Company
Glycogen Storage Disease Type II
Pompe Disease
The Pompe Registry is a global, multicenter, international, longitudinal, observational,
and voluntary program for patients with Pompe disease, designed to track the disease's
natural history and outcomes in patients, both treated and not. Data from the Registry
are also used to fulfill various glo1 expand
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: - To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention. - To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care. - To characterize the Pompe disease population. - To evaluate the long-term effectiveness of alglucosidase alfa. Type: Observational [Patient Registry] Start Date: Sep 2004 |
|
Dapagliflozin in Active Lupus Nephritis
Brigham and Women's Hospital
Lupus Nephritis (LN)
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that
predominately impacts young people and can lead to kidney failure. Sodium-glucose
co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for
people with other causes of chronic kid1 expand
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials. Type: Interventional Start Date: May 2026 |
|
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
Elion Therapeutics, Inc.
Invasive Mould Infection
The purpose of this study is to determine if EL219 is safe and effective compared to
liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould
infections expand
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections Type: Interventional Start Date: Feb 2026 |
|
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
Massachusetts General Hospital
Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
This is a single-arm pilot feasibility study evaluating the combination of Botensilimab
and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High
(MSI-H) or Proficient Mismatch Repair (pMMR) chemorefractory colorectal cancer (CRC) with
liver metastasis. expand
This is a single-arm pilot feasibility study evaluating the combination of Botensilimab and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High (MSI-H) or Proficient Mismatch Repair (pMMR) chemorefractory colorectal cancer (CRC) with liver metastasis. Type: Interventional Start Date: May 2026 |
|
Finding Links Between Hot flASHes and CardioVascular Disease
Massachusetts General Hospital
Menopause-related Hot Flashes
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor
antagonist elinzanetant improves blood vessel health in women with moderate to severe hot
flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor
antagonist elinzanetant improve blood1 expand
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health? Type: Interventional Start Date: Mar 2026 |
|
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Pla1
Kardigan, Inc.
Moderate Aortic Valve Stenosis
The purpose of this study is to evaluate if ataciguat slows the progression of moderate
calcific aortic valve stenosis in adults. expand
The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults. Type: Interventional Start Date: Jun 2025 |
|
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Pati1
Tango Therapeutics, Inc.
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
NSCLC
RAS Mutation
MTAP Deletion
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the
safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in
combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study
comprises a dose escalation phase and1 expand
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase. Type: Interventional Start Date: May 2025 |
|
Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
Massachusetts General Hospital
Depression - Major Depressive Disorder
Cannabis Use Disorder
Mental Disorder
The purpose of this study is to examine the feasibility, acceptability, and preliminary
efficacy of a digital intervention for co-occurring cannabis use and depression.
Participants will be randomized to complete Amplification of Positivity - Cannabis Use
(AMP-C) or symptom tracking. The main outco1 expand
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings. Type: Interventional Start Date: Feb 2026 |
|
Digital Sleep Optimization for Brain Health Outcomes in Older Surgical Patients
Massachusetts General Hospital
Insomnia
Postoperative Delirium
Delayed Neurocognitive Recovery
Postoperative Neurocognitive Disorder
The Sleep Optimization for Brain Health Outcomes in Older Surgical Patients (SLEEP-BOOST)
is a pilot randomized, controlled, singled-blinded (participant) trial in major
orthopedic joint surgery patients that will build on a previously clinically tested
cognitive behavioral therapy for insomnia (CB1 expand
The Sleep Optimization for Brain Health Outcomes in Older Surgical Patients (SLEEP-BOOST) is a pilot randomized, controlled, singled-blinded (participant) trial in major orthopedic joint surgery patients that will build on a previously clinically tested cognitive behavioral therapy for insomnia (CBT-I) mobile application paired with a wearable device (wrist actigraphy). Type: Interventional Start Date: Jan 2025 |
|
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
The University of Texas Medical Branch, Galveston
Chronic Subdural Hematoma
The goal of this clinical trial is to test in moderately symptomatic chronic subdural
hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an
alternative to conventional open surgery. The main questions it aims to answer are:
- Compared to open conventional sur1 expand
The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are: - Compared to open conventional surgery, does MMAE reduce the need for rescue surgery or deaths? - What is the safety of MMAE and conventional open surgery in these patients? Participants will be asked to: - Share their medical history and undergo physical examinations - Have blood drawn - Have CT scans of the head - Answer questionnaires - Undergo MMAE or conventional open surgery - Provide information about possible adverse events Researchers will compare participants in the MMAE group with those in the conventional open surgery group to see if there is a reduced need for rescue surgery or deaths and evaluate safety. Type: Interventional Start Date: Nov 2024 |